Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 14, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction involving the disposition of 217 shares of common stock.
- The shares were withheld by the issuer to satisfy the mandatory tax withholding requirement upon the vesting of restricted stock units.
- Following the transaction, Miller directly owns 37,065 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock transaction |
| 02/19/2025 | Date of signature for the filing |
Keywords
Acrivon Therapeutics, Form 4, SEC Filing, Stock Transaction, Mary Miller, Chief Legal Officer, ACRV, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.